DeepVessel FFR
Commercial- Indications
- Coronary artery disease
Company intelligence / Profile preview
Keya Medical’s flagship product DEEPVESSEL FFR provides non-invasive coronary artery assessment using CCTA. It has demonstrated high accuracy in clinical studies—92% accuracy in a single-center retrospective study at Fuwai Hospital—and has completed the ADAPT clinical trial. The TARGET randomized trial was presented at ACC 2023. The product is commercially available in the US, EMEA region, China, and Singapore.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Keya Medical.